Study Finds No Increased Risk of Suicidal Thoughts from GLP-1 Use in Novo Nordisk's Success

Study finds no increased risk of suicidal thoughts due to GLP-1 use

The European Union's drug regulators have been investigating whether GLP-1s such as Wegovy and Ozempic could be linked to suicidal thoughts. But in April, they concluded that there was no evidence to support that there is an increased risk as a result of using these types of drugs. The nine-month study puts to rest one of the more alarming concerns that has been raised around these GLP-1 drugs. But it's important to note that it didn't include all GLP-1 drugs; Eli Lilly's Zepbound and Mounjaro, for example, weren't included in the study.

Novo Nordisk's sales took off last year, thanks to Ozempic and Wegovy

To truly understand the importance of these recent findings, investors just need to look at Novo Nordisk's financials for last year. In 2023, Ozempic generated revenue of 95.7 billion Danish krone ($14.4 billion), and it was the company's top product, representing 41% of Novo Nordisk's sales, which totaled 232.3 billion Danish krone ($34.8 billion). Ozempic's sales rose by 60%, and the company's top line increased by 31%.

Novo Nordisk may be a top growth stock to own for years

Over the past 12 months, shares of Novo Nordisk have risen by more than 50%. Although it may not be as diversified as other healthcare companies, with some incredibly popular and successful assets in Wegovy and Ozempic, Novo Nordisk could be a top growth stock to buy for the long haul.